{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:27:50Z","timestamp":1787574470764,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the feasibility of prenatal cell-free DNA (cfDNA) screening with fetal fraction amplification between 6 and 9 weeks of gestation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      Pregnant individuals underwent two blood draws: the first between 6 0\/7 and 9 6\/7 weeks of gestation and the second at 10 0\/7 weeks or later. Samples were processed using a cfDNA screen with fetal fraction amplification. Before the implementation of fetal fraction amplification, 4.8% of samples drawn at 10 0\/7 weeks of gestation had\n                      <jats:italic toggle=\"yes\">low fetal fraction<\/jats:italic>\n                      , defined as less than 4%. Logistic regression was used to determine the earliest gestational age after the implementation of fetal fraction amplification at which the proportion of samples with low fetal fraction was 4.8% or less. Positive and negative percent agreements were calculated for samples collected before and after 10 0\/7 weeks of gestation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Among 562 patients enrolled, 470 completed two blood draws and were included in the analysis. Median maternal age was 32 years (IQR 29\u201334 years), and median body mass index (BMI) was 25.7 (IQR 22.7\u201330.9). Median fetal fraction was 9.0% (IQR 6.5\u201313.6) for samples drawn at 6 0\/7\u20139 6\/7 weeks of gestation and 18.5% (IQR 14.4\u201323.9%) for those drawn at 10 0\/7 weeks or later. Among patients with BMI 30 or higher (n=125), the median fetal fraction was 7.2% (IQR 5.5\u201310.7%) for samples drawn at 6 0\/7\u20139 6\/7 weeks of gestation and 14.7% (IQR 11.3\u201318.5) for those drawn at 10 0\/7 weeks or later. The gestational age at which 4.8% of samples had low fetal fraction was 7 3\/7 weeks. The screen failure rate was 1.5% (7\/470) for samples drawn at 6 0\/7\u20139 6\/7 weeks of gestation and 0.3% (1\/291) for samples drawn at 7 3\/7\u20139 6\/7 weeks. Because patients often present for routine prenatal care beginning in the 8th week of gestation, we also calculated performance at 8 0\/7\u20139 6\/7 weeks. During this period, the screen failure rate was 0.4% (1\/241), and both positive and negative percent agreements were 100% for all screened aneuploidies. At 10 0\/7 weeks of gestation or later, two samples were called positive for trisomy 21 and one for trisomy 7; their corresponding samples at 8 0\/7\u20139 6\/7 weeks were also called positive. Fetal sex call concordance was 100% for both XX (110\/110) and XY (130\/130).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Fetal fraction amplification enables cfDNA screening beginning at 7 3\/7 weeks of gestation. Performance and concordance data are limited but suggest the clinical feasibility of offering cfDNA screening with fetal fraction amplification beginning at 8 weeks of gestation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006324","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T21:02:40Z","timestamp":1779397360000},"page":"149-156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6\u20139 Weeks of Gestation"],"prefix":"10.1097","volume":"148","author":[{"given":"Lorraine","family":"Dugoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Mabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhett","family":"Bordwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Johansen Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Muzzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"R1-20260824","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(97)02174-0","article-title":"Presence of fetal DNA in maternal plasma and serum","volume":"350","author":"Lo","year":"1997","journal-title":"Lancet"},{"key":"R2-20260824","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/uog.17484","article-title":"Analysis of cell\u2010free DNA in maternal blood in screening for aneuploidies: updated meta\u2010analysis","volume":"50","author":"Gil","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R3-20260824","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1056\/NEJMra1705345","article-title":"Sequencing of circulating cell-free DNA during pregnancy","volume":"379","author":"Bianchi","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20260824","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/gim.2016.97","article-title":"Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics","volume":"18","author":"Gregg","year":"2016","journal-title":"Genet Med"},{"key":"R5-20260824","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1097\/AOG.0000000000001406","article-title":"Screening for fetal aneuploidy. Practice Bulletin No. 163. American College of Obstetricians & Gynecologists","volume":"127","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R6-20260824","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/AOG.0000000000004084","article-title":"Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 226. American College of Obstetricians & Gynecologists","volume":"136","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R7-20260824","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pd.5620","article-title":"Fetal fraction and noninvasive prenatal testing: what clinicians need to know","volume":"40","author":"Hui","year":"2020","journal-title":"Prenat Diagn"},{"key":"R8-20260824","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/pd.5152","article-title":"The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction","volume":"37","author":"Burns","year":"2017","journal-title":"Prenat Diagn"},{"key":"R9-20260824","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41436-020-01009-5","article-title":"High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening","volume":"23","author":"Welker","year":"2021","journal-title":"Genet Med"},{"key":"R10-20260824","doi-asserted-by":"crossref","first-page":"345.e1","DOI":"10.1016\/j.ajog.2019.05.023","article-title":"Sequencing shorter cfDNA fragments improves the fetal DNA fraction in noninvasive prenatal testing","volume":"221","author":"Qiao","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R11-20260824","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12967-022-03555-9","article-title":"A fetal fraction enrichment method reduces false negatives and increases test success rate of fetal chromosome aneuploidy detection in early pregnancy loss","volume":"20","author":"Qiao","year":"2022","journal-title":"J Transl Med"},{"key":"R12-20260824","doi-asserted-by":"crossref","first-page":"103458","DOI":"10.1016\/j.gimo.2025.103458","article-title":"Real-life implementation of prenatal cell-free DNA screening with in vitro fetal enrichment virtually eliminates the need for redraws and improves performance: a cohort study","volume":"3","author":"Giroux","year":"2025","journal-title":"Genet Med Open"},{"key":"R13-20260824","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/AOG.0000000000005889","article-title":"Tailored prenatal care delivery for pregnant individuals. ACOG Clinical Consensus No. 8. American College of Obstetricians & Gynecologists","volume":"145","year":"2025","journal-title":"Obstet Gynecol"},{"key":"R14-20260824","doi-asserted-by":"crossref","first-page":"16266","DOI":"10.1073\/pnas.0808319105","article-title":"Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood","volume":"105","author":"Fan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20260824","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/uog.21904","article-title":"Clinical experience across the fetal\u2010fraction spectrum of a non\u2010invasive prenatal screening approach with low test\u2010failure rate","volume":"56","author":"Hancock","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R16-20260824","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/cge.70020","article-title":"Prenatal cell-free DNA screening with fetal enrichment enables sampling from 8 weeks of gestational age","volume":"109","author":"Daryabari","year":"2026","journal-title":"Clin Genet"},{"key":"R17-20260824","doi-asserted-by":"crossref","first-page":"777.e1","DOI":"10.1016\/j.ajog.2016.08.011","article-title":"Revisiting the challenges of training maternal fetal medicine fellows in chorionic villus sampling","volume":"215","author":"Suskin","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20260824","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0140-6736(22)02610-1","article-title":"Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study","volume":"401","author":"Schlaikj\u00e6r Hartwig","year":"2023","journal-title":"Lancet"},{"key":"R20-20260824","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bdra.23014","article-title":"A systematic review to calculate background miscarriage rates using life table analysis","volume":"94","author":"Ammon Avalos","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R21-20260824","first-page":"1","article-title":"Prepregnancy body mass index by maternal characteristics and state: data from the birth certificate, 2014","volume":"65","author":"Branum","year":"2016","journal-title":"Natl Vital Stat Rep"},{"key":"R22-20260824","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/pd.6562","article-title":"High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplification","volume":"44","author":"Hammer","year":"2024","journal-title":"Prenat Diagn"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:01:01Z","timestamp":1787572861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006324","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"2025-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}